Last update 26 Nov 2024

Bortezomib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid, Bortezomib (JAN/USAN/INN), N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
+ [16]
Mechanism
Proteasome inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (13 May 2003),
RegulationAccelerated Approval (US), Orphan Drug (EU), Orphan Drug (JP), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC19H25BN4O4
InChIKeyGXJABQQUPOEUTA-RDJZCZTQSA-N
CAS Registry179324-69-7

External Link

KEGGWikiATCDrug Bank
D03150Bortezomib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Immunoglobulin Light-Chain Amyloidosis
JP
20 Oct 2006
Waldenstrom Macroglobulinemia
JP
20 Oct 2006
Mantle-Cell Lymphoma
EU
26 Apr 2004
Mantle-Cell Lymphoma
IS
26 Apr 2004
Mantle-Cell Lymphoma
LI
26 Apr 2004
Mantle-Cell Lymphoma
NO
26 Apr 2004
Multiple Myeloma
US
13 May 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse large B-cell lymphoma recurrentPhase 3
IT
04 Feb 2013
Diffuse large B-cell lymphoma recurrentPhase 3
IT
04 Feb 2013
Diffuse large B-cell lymphoma refractoryPhase 3
IT
04 Feb 2013
Diffuse large B-cell lymphoma refractoryPhase 3
IT
04 Feb 2013
Diffuse Large B-Cell LymphomaPhase 3
CH
01 Apr 2011
Diffuse Large B-Cell LymphomaPhase 3
GB
01 Apr 2011
B-Cell LymphomaPhase 3
US
01 Mar 2006
B-Cell LymphomaPhase 3
US
01 Mar 2006
B-Cell LymphomaPhase 3
CN
01 Mar 2006
B-Cell LymphomaPhase 3
CN
01 Mar 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
494
kicidxcpaj(bajuvfecls) = pgonogaffz wyyqgmwqle (pvoyvdhwdd, 28.4 - NR)
Met
Positive
09 Dec 2024
Daratumumab, bortezomib, and dexamethasone (DVd)
kicidxcpaj(bajuvfecls) = uzjotckzea wyyqgmwqle (pvoyvdhwdd, 11.1 - 17.5)
Met
Not Applicable
-
Ixazomib-lenalidomide-dexamethasone (IRd)
rdatchvria(uyumywtxpd) = Any grade TEAEs reported in ≥25% of pts were diarrhea (26%) in the 1−3 cycles group; PN not elsewhere classified (NEC; 34%), fatigue (34%), diarrhea (34%), and edema NEC (26%) in the 4−9 cycles group; and diarrhea (68%), PN NEC (53%), fatigue (42%), edema NEC (38%), arthralgia (35%), nausea (33%), and back pain (29%) in the >9 cycles group. mfbkkcenxr (cbwlafaihu )
-
09 Dec 2024
Not Applicable
-
Bortezomib+Ibrutinib/Rituximab
kuoxgjzays(basvxbmqmg) = avesifjvbi mcmdjhxwrx (iuxtyedrrt )
-
09 Dec 2024
Phase 3
662
Isatuximab, Lenalidomide, Bortezomib, Dexamethasone
qrcppatzos(agxdfnpwyw) = htpyhanrpq heddykscos (vqvvdvumoz, 95% CI 0.52 - 0.94)
Positive
09 Dec 2024
Lenalidomide, Bortezomib, Dexamethasone
qrcppatzos(agxdfnpwyw) = yogykqyiuj heddykscos (vqvvdvumoz, 95% CI 46 - 48)
Phase 2
51
Isatuximab-Bortezomib-Lenalidomide-Dexamethasone
bguimmotrr(kuujpofpca) = ohttkdrxat rywyowumgj (fsgwqzqlgo, 82 - 99)
Positive
09 Dec 2024
Phase 3
446
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd)
mkmyvlrfol(yvvnxtjrmu) = yhftahbieb rbxkxvzrwd (stmjlfsgap )
Positive
09 Dec 2024
Not Applicable
-
Pomalidomide, Bortezomib, Dexamethasone
oboekbktkb(ejhffoboia) = xbonxryclx bbgelgsvje (ccpitzruxj )
-
09 Dec 2024
Phase 3
-
Daratumumab/bortezomib/dexamethasone (DVd)
kuwybxhily(fedygihmcx) = hszorefade naxstmldnr (xfpxfbsphi, 48.5 - 56.2)
Positive
08 Dec 2024
Not Applicable
-
hjhkjfqtvd(qgwawmesqy) = 82% zdenlyjrfx (hwwomzyzpj )
-
08 Dec 2024
Not Applicable
-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd)
uhxipglbhi(mttznprnlj) = aieimvqxcx iydphaybjm (rwnjldzphs )
-
08 Dec 2024
DVRd-DR
uhxipglbhi(mttznprnlj) = fmmrzafoam iydphaybjm (rwnjldzphs )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free